Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3LFDH)

• Drug Name: AZD9977 Drug Info
• Synonyms: AZD9977; AZD-9977; 1850385-64-6; BALCINRENONE; UNII-6C9UKZ0CYE; 6C9UKZ0CYE; Azd 9977; 2-[(3S)-7-Fluoro-4-(3-oxo-4H-1,4-benzoxazine-6-carbonyl)-2,3-dihydro-1,4-benzoxazin-3-yl]-N-methylacetamide; 2H-1,4-Benzoxazine-3-acetamide, 4-((3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)carbonyl)-7-fluoro-3,4-dihydro-N-methyl-, (3S)-; 2-[(3~{S})-7-fluoranyl-4-[(3-oxidanylidene-4~{H}-1,4-benzoxazin-6-yl)carbonyl]-2,3-dihydro-1,4-benzoxazin-3-yl]-~{N}-methyl-ethanamide; 2-((3S)-7-FLUORO-4-((3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZIN-6-YL)CARBONYL)-3,4-DIHYDRO-2H-1,4-BENZOXAZIN-3-YL)-N-METHYLACETAMIDE; 2-{(3S)-7-Fluoro-4-[(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)carbonyl]-3,4-dihydro-2H-1,4-benzoxazin-3-yl}-N-methylacetamide; BALCINRENONE [INN]; CHEMBL3916929; SCHEMBL17363859; GTPL11281; AZD 9977 [WHO-DD]; MBKYLPOPYYLTNW-ZDUSSCGKSA-N; BDBM238159; AKOS040759623; DB15418; US9394291, 4a; AC-36749; MS-26766; HY-120274; CS-0077469; F82308; (S)-1 [PMID: 30596500]; ECV

Indication

Disease Entry	ICD 11	Status	REF
Heart failure	BD10-BD13	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 118599727
  TTD Drug ID: DM3LFDH

Molecule-Related Drug Atlas

Drug(s) Targeting Mineralocorticoid receptor (MR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aldosterone	DM9S2JW	Hypertension	BA00-BA04	Approved	[3]
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[4]
Fludrocortisone	DMUDIR8	Addison disease	5A74.0	Approved	[5]
Desoxycorticosterone Acetate	DMS0AFE	Discovery agent	N.A.	Approved	[4]
Desoxycorticosterone Pivalate	DMSA4B3	Addison disease	5A74.0	Approved	[6]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[7]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[4]
Finerenone	DMM4FJ3	Chronic kidney disease	GB61	Approved	[8]
ZK-91587	DMJ94L0	Cardiovascular disease	BA00-BE2Z	Phase 2	[9]
Nerenone	DMBJ3GL	Diabetic nephropathy	GB61.Z	Phase 2	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Mineralocorticoid receptor (MR)	TT26PHO	MCR_HUMAN	Modulator	[2]

References

• [1] ClinicalTrials.gov (NCT04595370) A Phase 2b, Randomised, Double-Blind, Active Controlled, Multi Centre Study to Evaluate the Efficacy, Safety and Tolerability of Oral AZD9977 and Dapagliflozin Treatment in Patients With Heart Failure and Chronic Kidney Disease. U.S.National Institutes of Health.
• [2] The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone. J Renin Angiotensin Aldosterone Syst. 2019 Jan-Mar;20(1):1470320319827449.
• [3] Stimulation of testosterone production in rat Leydig cells by aldosterone is mineralocorticoid receptor mediated. Mol Cell Endocrinol. 2005 Nov 24;243(1-2):35-42.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Mineralocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans. J Gerontol A Biol Sci Med Sci. 2003 Oct;58(10):B900-5.
• [6] Characterization of rat brain aldosterone receptors reveals high affinity for corticosterone. Endocrinology. 1983 Dec;113(6):2043-51.
• [7] Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and ... Curr Top Med Chem. 2006;6(5):461-78.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] ZK91587: a novel synthetic antimineralocorticoid displays high affinity for corticosterone (type I) receptors in the rat hippocampus. Life Sci. 1988;43(19):1537-43.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 626).